IDEXX Laboratories' CEO Discusses Q4 2012 Results – Earnings Call Transcript

IDEXX Laboratories' CEO Discusses Q4 2012 Results – Earnings Call Transcript
Filed under: dual diagnosis clinic

Also in Q4 and for the year, roughly 80% of ProCyte were sold to Catalyst customers with approximately 60% of that subset being to temporaneous purchase of both instruments, evidence of the important role that the dual plays in enabling real-time care …
{Source}